Pomalyst FDA Approval History
FDA Approved: Yes (First approved February 8, 2013)
Brand name: Pomalyst
Generic name: pomalidomide
Dosage form: Capsules
Company: Bristol-Myers Squibb Company
Treatment for: Multiple Myeloma, Kaposi's Sarcoma
Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma and AIDS-related and HIV-negative Kaposi sarcoma.
Development Timeline for Pomalyst
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.